PT3134119T - Tratamento do cancro - Google Patents

Tratamento do cancro

Info

Publication number
PT3134119T
PT3134119T PT15729222T PT15729222T PT3134119T PT 3134119 T PT3134119 T PT 3134119T PT 15729222 T PT15729222 T PT 15729222T PT 15729222 T PT15729222 T PT 15729222T PT 3134119 T PT3134119 T PT 3134119T
Authority
PT
Portugal
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Application number
PT15729222T
Other languages
English (en)
Portuguese (pt)
Inventor
Andre Martini Jean-Francois
Christo Tarazi Jamal
Andrew Williams James
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PT3134119T publication Critical patent/PT3134119T/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
PT15729222T 2014-04-24 2015-04-16 Tratamento do cancro PT3134119T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983951P 2014-04-24 2014-04-24

Publications (1)

Publication Number Publication Date
PT3134119T true PT3134119T (pt) 2018-11-07

Family

ID=53398149

Family Applications (1)

Application Number Title Priority Date Filing Date
PT15729222T PT3134119T (pt) 2014-04-24 2015-04-16 Tratamento do cancro

Country Status (23)

Country Link
US (2) US20170184602A1 (enExample)
EP (1) EP3134119B1 (enExample)
JP (1) JP6603474B2 (enExample)
KR (1) KR101943177B1 (enExample)
CN (1) CN106233143B (enExample)
AR (1) AR100169A1 (enExample)
AU (3) AU2015249513A1 (enExample)
BR (1) BR112016024143A2 (enExample)
CA (1) CA2946362C (enExample)
CY (1) CY1120731T1 (enExample)
DK (1) DK3134119T3 (enExample)
ES (1) ES2691213T3 (enExample)
HU (1) HUE040167T2 (enExample)
IL (1) IL247859B (enExample)
MX (1) MX375794B (enExample)
PL (1) PL3134119T3 (enExample)
PT (1) PT3134119T (enExample)
RU (1) RU2651469C1 (enExample)
SG (1) SG11201607918TA (enExample)
SI (1) SI3134119T1 (enExample)
TR (1) TR201815682T4 (enExample)
TW (1) TWI568439B (enExample)
WO (1) WO2015162532A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6945199B2 (ja) 2017-05-19 2021-10-06 国立大学法人山口大学 アキシチニブの薬物動態判定方法及びアキシチニブの薬物動態に基づくアキシチニブによる治療効果予測方法
WO2020014666A1 (en) * 2018-07-12 2020-01-16 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
KR102767594B1 (ko) * 2018-07-12 2025-02-12 코버스 파마슈티칼스, 인크. 아데노신 경로 활성화를 갖는 암의 검출 및 치료 방법
US11409549B2 (en) 2018-10-15 2022-08-09 AIble Inc. Interface for generating models with customizable interface configurations
US10586164B1 (en) 2018-10-15 2020-03-10 AIble Inc. Interface for visualizing and improving model performance
US10936768B2 (en) * 2018-10-15 2021-03-02 Aible, Inc. Interface for visualizing and improving model performance
US12656349B2 (en) 2019-10-17 2026-06-16 Board Of Regents, The University Of Texas System Measurement of bevacizumab-insensitive vascular endothelial growth factor-a
JP2025518482A (ja) * 2022-05-11 2025-06-17 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ 膵臓癌および２型糖尿病のための診断マーカーとしてのｂｍｍｆ１ ｒｅｐタンパク質の使用
CA3252723A1 (en) * 2022-05-11 2023-11-16 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts USE OF A REP PROTEIN BMMF1 AS A DIAGNOSTIC MARKER FOR LUNG CANCER
EP4562058A4 (en) * 2022-07-28 2026-08-19 Univ Oklahoma BIOMARKERS, DIAGNOSTIC METHODS, TREATMENTS AND THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES AND DISORDERS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509613A (ja) 2003-10-16 2007-04-19 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現プロファイリングのためのｑＲＴ−ＰＣＲアッセイシステム
CA2563074C (en) * 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
CN101506351A (zh) * 2005-10-21 2009-08-12 拜尔健康护理有限责任公司 用于癌症预测和预后及监测癌症治疗的方法
US20070128636A1 (en) * 2005-12-05 2007-06-07 Baker Joffre B Predictors Of Patient Response To Treatment With EGFR Inhibitors
BRPI0715062A2 (pt) * 2006-07-28 2013-06-04 Novartis Ag mÉtodos para determinar uma resposta de um indivÍduo mamÍfero que tem cÉlulas de tumor de melanoma ao tratamento com um agente inibidor de melanoma, para avaliar a eficÁcia de um agente inibidor de melanoma para tratar melanoma em um indivÍduo mamÍfero que tem melanoma, para determinar se um paciente deve continuar a receber tratamento com um agente inibidor de melanoma e para identificar agente que tÊm utilidade no tratamento de melanoma
EP2088863A2 (en) * 2006-11-22 2009-08-19 University Of Georgia Research Foundation, Inc. Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
SG10201403896XA (en) * 2009-07-08 2014-10-30 Worldwide Innovative Network Method for predicting efficacy of drugs in a patient
KR101557545B1 (ko) * 2009-09-17 2015-10-06 에프. 호프만-라 로슈 아게 암 환자에서 진단 용도를 위한 방법 및 조성물
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
WO2012052757A1 (en) * 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
WO2012068487A1 (en) * 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
AU2012318618B2 (en) * 2011-10-04 2017-01-12 Invivis Pharmaceuticals Inc. Methods and systems for identifying and treating anti-progestin sensitive tumors
CA2862835A1 (en) * 2012-01-13 2013-07-18 Genentech, Inc. Biological markers for identifying patients for treatment with vegf antagonists

Also Published As

Publication number Publication date
KR101943177B1 (ko) 2019-01-28
US20190331687A1 (en) 2019-10-31
CA2946362C (en) 2019-03-12
HUE040167T2 (hu) 2019-02-28
JP2015210268A (ja) 2015-11-24
BR112016024143A2 (pt) 2017-08-15
CY1120731T1 (el) 2019-12-11
AU2020200237A1 (en) 2020-02-06
HK1231561A1 (zh) 2017-12-22
AU2018203086A1 (en) 2018-05-24
SG11201607918TA (en) 2016-11-29
ES2691213T3 (es) 2018-11-26
MX2016013910A (es) 2017-01-11
JP6603474B2 (ja) 2019-11-06
DK3134119T3 (en) 2018-10-22
RU2651469C1 (ru) 2018-04-19
CN106233143B (zh) 2020-01-21
AR100169A1 (es) 2016-09-14
WO2015162532A1 (en) 2015-10-29
CN106233143A (zh) 2016-12-14
CA2946362A1 (en) 2015-10-29
TR201815682T4 (tr) 2018-11-21
MX375794B (es) 2025-03-07
PL3134119T3 (pl) 2018-12-31
TW201545747A (zh) 2015-12-16
AU2015249513A1 (en) 2016-10-06
SI3134119T1 (sl) 2018-11-30
KR20160134817A (ko) 2016-11-23
IL247859A0 (en) 2016-11-30
EP3134119A1 (en) 2017-03-01
IL247859B (en) 2020-07-30
EP3134119B1 (en) 2018-08-22
TWI568439B (zh) 2017-02-01
US20170184602A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
IL296080B1 (en) Method for treating cancer
IL255261A0 (en) Methods for treating cancer
DK3240801T3 (da) Kombinationstumorimmunterapi
IL251890A0 (en) Combination immunotherapy approach for treatment of cancer
HUE054012T2 (hu) Kombinációs terápia rák ellen
DK3590543T3 (da) Medicinsk forbinding
DK3506854T3 (da) Brystbehandlingsindretning
PL3197456T3 (pl) Leczenie nowotworów
IL258684A (en) Combination therapy for treating malignancies
DK3231444T3 (da) Ny behandling
KR20180084772A (ko) 암 치료를 위한 조합 치료법
EP3546020C0 (en) CANCER TREATMENT DEVICE
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
EP3413927A4 (en) CANCER THERAPY
PL3134119T3 (pl) Leczenie nowotworu
IL251903B (en) Apilimod for use in the treatment of colorectal cancer
DK3576740T3 (da) Cancerbehandling
EP3362091A4 (en) COMBINATION THERAPY
EP3576791A4 (en) CALRETICULIN-MEDIATION CANCER TREATMENT
HUE046894T2 (hu) Anamorelinen alapuló gyógyászati kezelések
IL246558A0 (en) Novel methods for treating cancer
DK3393478T3 (da) Kombinationsterapi
DK3302478T3 (da) Pac-1 kombinations behandling
IL264277A (en) Crebbp related cancer therapy
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도